Education
About Us
Working with TipRanks
Follow Us
NeueHealth Inc (NEUE)
NYSE:NEUE
Top Page
NeueHealth Inc
(NYSE:NEUE)
50Neutral
NeueHealth Inc (NEUE) vs. S&P 500 (SPY)
Market Cap
$59.37M
Dividend YieldN/A
Average Volume (3M)32.62K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth-42.06%
EPS Growth85.00%
CountryUS
Employees986
SectorHealthcare
Sector Strength65
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-22.63
Shares Outstanding8,927,758
10 Day Avg. Volume10,741
30 Day Avg. Volume32,622
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.07
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside4.01% Upside
Rating ConsensusHold
Number of Analyst Covering0
NeueHealth Inc Business Overview & Revenue Model
Company DescriptionNeueHealth Inc (NEUE) is a healthcare company focused on providing innovative solutions in the medical and wellness sectors. The company specializes in developing digital health platforms and services that aim to enhance patient care and streamline healthcare delivery. NeueHealth's core offerings include telemedicine services, healthcare data analytics, and personalized health management solutions.
How the Company Makes MoneyNeueHealth Inc generates revenue through a combination of subscription fees for its telemedicine platform, licensing fees for its healthcare data analytics tools, and service fees for personalized health management solutions. The company collaborates with healthcare providers and insurance companies to facilitate the integration of its solutions into existing healthcare systems, which enhances its market reach and revenue potential. Additionally, NeueHealth forms strategic partnerships with technology companies to co-develop and deploy cutting-edge digital health solutions, further contributing to its earnings.
NeueHealth Inc Financial Statement Overview
Summary
NeueHealth Inc faces significant financial challenges with declining revenues, consistent losses, and a weak balance sheet. Despite some cash flow improvements, the company struggles with profitability and financial stability. High liabilities relative to assets and negative equity raise concerns about solvency and long-term viability.Income Statement
NeueHealth Inc has shown a decline in revenue and profitability over the years. The gross profit margin has decreased significantly, and net profit margins remain negative, indicating persistent losses. Revenue growth rate is erratic, with recent declines. The company has negative EBIT and EBITDA margins, highlighting operational inefficiencies.45
Neutral
Balance Sheet
The balance sheet reveals a concerning financial structure with negative stockholders' equity, indicating possible insolvency. The debt-to-equity ratio is not meaningful due to negative equity, but the company has managed to keep its total debt relatively low. However, the equity ratio is negative, reflecting poor financial health and substantial liabilities compared to assets.30
Negative
Cash Flow
Cash flow statements show fluctuating free cash flow with recent improvements, yet still negative. Operating cash flow is consistently negative, reflecting challenges in generating cash from operations. The free cash flow to net income ratio is not favorable, indicating inefficiencies in converting profits into cash.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 936.66M | 1.16B | 751.16M | 1.51B | 514.89M | Gross Profit |
| 194.52M | 164.22M | 88.19M | 218.88M | 62.97M | EBIT |
| -102.06M | -577.00M | -368.76M | -343.63M | -170.38M | EBITDA |
| -65.11M | -566.80M | -246.39M | -308.58M | -249.31M | Net Income Common Stockholders |
| -134.68M | -1.15B | -1.46B | -1.18B | -248.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 93.17M | 93.56M | 217.88M | 433.76M | 988.30M | Total Assets |
| 544.38M | 1.23B | 4.67B | 3.60B | 1.81B | Total Debt |
| 2.00M | 370.35M | 303.95M | 155.00M | 28.42M | Net Debt |
| -81.30M | 283.05M | 86.94M | -134.28M | -459.95M | Total Liabilities |
| 930.49M | 1.48B | 3.73B | 2.32B | 2.27B | Stockholders Equity |
| -1.36B | -343.53M | 719.93M | 1.15B | -503.67M |
| Cash Flow | Free Cash Flow | |||
| -125.55M | -2.73B | 207.02M | 51.65M | -63.71M | Operating Cash Flow |
| -123.22M | -2.73B | 234.47M | 82.06M | -57.24M | Investing Cash Flow |
| 186.89M | 1.12B | -429.72M | -552.89M | -689.74M | Financing Cash Flow |
| -253.55M | 49.91M | 1.07B | 1.04B | 712.44M |
NeueHealth Inc Technical Analysis
Positive
6.73
Price Trends
6.65
Positive
6.53
Positive
5.90
Positive
Market Momentum
0.02
Negative
54.80
Neutral
72.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Positive. The current price of 6.73 is above the 20-day moving average (MA) of 6.53, above the 50-day MA of 6.65, and above the 200-day MA of 5.90, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.80 is Neutral, neither overbought nor oversold. The STOCH value of 72.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEUE.
NeueHealth Inc Risk Analysis
NeueHealth Inc disclosed 58 risk factors in its most recent earnings report. NeueHealth Inc reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeueHealth Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.72B | 16.36 | 15.57% | 0.30% | ― | ― | |
61 Neutral | $59.67M | ― | 17.16% | ― | -5.32% | 95.20% | |
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
50 Neutral | $59.37M | ― | 84.03% | ― | -42.06% | 85.00% | |
45 Neutral | $60.41M | ― | -61.03% | ― | 16.84% | 9.43% | |
37 Underperform | $57.42M | ― | -50.06% | ― | -77.09% | 63.49% | |
36 Underperform | $68.09M | ― | -130.38% | ― | 134.56% | 61.91% |
* Healthcare Sector Average
Performance Comparison
NEUE
NeueHealth Inc
6.73
0.62
10.15%
CCLD
CareCloud
1.67
0.59
54.63%
AVTX
Avalo Therapeutics
4.88
-11.06
-69.39%
CBUS
Cibus
1.99
-13.85
-87.44%
HYPR
Hyperfine
0.78
-0.06
-7.14%
CON
Concentra Group Holdings Parent, Inc.
21.26
-1.46
-6.43%
NeueHealth Inc Earnings Call Summary
Earnings Call Date: Mar 20, 2025 | % Change Since: 39.05% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook for NeueHealth, with significant growth in consumer numbers, strong financial performance, and strategic expansions into new markets. The agreement to be acquired is viewed as a positive move, providing flexibility and resources for further growth. However, there was a noted operating loss in the NeueSolutions segment.Highlights
Strongest Financial Year to Date
NeueHealth delivered its strongest year of financial performance in 2024, achieving $936.7 million in consolidated revenue and $22.5 million in adjusted EBITDA for the full year.
Significant Consumer Growth
The company served 483,000 consumers in 2024, representing a compound annual growth rate of 123% since 2020. In early 2025, they have already grown to serve 717,000 consumers.
Expansion into New Markets
NeueHealth expanded its operations into new markets, achieving a 97% growth in consumers served in newly expanded markets.
Acquisition Agreement
NeueHealth entered into a definitive agreement to be acquired by an affiliate of one of its largest investors, NEA, which positions the company for continued growth as a privately held entity.
NeueCare Segment Performance
The NeueCare segment achieved $79.3 million in revenue for Q4 and $313.7 million for the full year, with a full year operating income of $29.6 million.
NeueSolutions Segment Growth
NeueSolutions generated $157.1 million in revenue in Q4 and $635.1 million for the full year, with strong growth in the provider enablement business.
Lowlights
Operating Loss in NeueSolutions
The NeueSolutions segment reported an operating loss of $5.3 million for the full year despite revenue growth.
Company Guidance
During the Q4 2024 earnings call for NeueHealth, CEO Mike Mikan detailed the company's robust financial performance, highlighting a full-year consolidated revenue of $936.7 million and an adjusted EBITDA of $22.5 million. The company served 483,000 consumers, marking a compound annual growth rate of 123% since 2020, with an increase to 717,000 consumers at the start of 2025. NeueHealth reported Q4 revenue of $232.6 million and a gross margin of $47.7 million. The NeueCare segment achieved a full-year revenue of $313.7 million, serving 318,000 value-based consumers, while the NeueSolutions segment reported $635.1 million in revenue, serving 123,000 consumers. As of December 31, 2024, the company held $202.8 million in total cash and investments. Additionally, NeueHealth announced a definitive agreement to be acquired by an affiliate of NEA, anticipating the transaction to close in Q2 2025.NeueHealth Inc Corporate Events
M&A TransactionsBusiness Operations and Strategy
NeueHealth Inc Completes Acquisition of Centrum Health
Positive
Oct 30, 2024
NeueHealth, Inc. has acquired full ownership of Centrum Health by purchasing the remaining 25% equity it didn’t own, streamlining its operations to focus on its value-driven, consumer-centric care model. This strategic move is expected to enhance coordination and seamless healthcare experiences, positioning NeueHealth for success in future healthcare markets. The acquisition involves a total consideration of $101.75 million, including cash, credits, and a secured promissory note.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.